Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR‐mutant nonsmall cell lung cancer with brain metastasis
Y Zhao, S Li, X Yang, L Chu, S Wang… - … journal of cancer, 2022 - Wiley Online Library
Osimertinib, as a third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI), showed more potent efficacy against brain metastasis (BM) in untreated …
inhibitor (TKI), showed more potent efficacy against brain metastasis (BM) in untreated …
[PDF][PDF] The value of EGFR in individualized treatment for brain metastases in non-small cell lung cancer
L Tan, J Ren - Cell Signal, 2023 - probiologists.com
The prognosis of brain metastases in non-small cell lung cancer (NSCLC) is poor, and
patients with EGFR mutations are more likely to have brain metastases. The epidermal …
patients with EGFR mutations are more likely to have brain metastases. The epidermal …
Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases
IM Goldstein, LC Roisman… - Neuro-Oncology …, 2020 - academic.oup.com
Background Osimertinib is a selective irreversible epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI) with increased penetration across the blood–brain barrier …
kinase inhibitor (EGFR-TKI) with increased penetration across the blood–brain barrier …
Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
K Liu, G Jiang, A Zhang, Z Li, J Jia - BMC cancer, 2020 - Springer
Background The prognosis of non-small-cell lung cancer (NSCLC) with brain metastases is
very poor. Currently, therapeutic methods for this patient population include whole-brain …
very poor. Currently, therapeutic methods for this patient population include whole-brain …
Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: two case reports
T Koba, T Kijima, T Takimoto, H Hirata, Y Naito… - Medicine, 2017 - journals.lww.com
Rationale: Most of nonsmall cell lung cancer (NSCLC) patients harboring epidermal growth
factor receptor (EGFR) activating mutations eventually acquire resistance to the first EGFR …
factor receptor (EGFR) activating mutations eventually acquire resistance to the first EGFR …
[HTML][HTML] A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or …
Background Up to 40% of patients with non-small-cell lung cancer (NSCLC) and epidermal
growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors (TKIs) …
growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors (TKIs) …
Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+ …
Background Patients with advanced non-small-cell lung cancer (NSCLC) with activating
mutations in the epidermal growth factor receptor (EGFR) gene are a heterogeneous …
mutations in the epidermal growth factor receptor (EGFR) gene are a heterogeneous …
The optimal therapy strategy for epidermal growth factor receptor‐mutated non‐small cell lung cancer patients with brain metastasis: A real‐world study from Taiwan
Background The treatment options for epidermal growth factor receptor (EGFR)‐mutated
non‐small cell lung cancer (NSCLC) with brain metastases (BMs) include EGFR‐tyrosine …
non‐small cell lung cancer (NSCLC) with brain metastases (BMs) include EGFR‐tyrosine …
Effects of epidermal growth factor receptor‐tyrosine kinase inhibitors alone on EGFR‐mutant non‐small cell lung cancer with brain metastasis
Q Zhang, X Zhang, H Yan, B Jiang, C Xu… - Thoracic …, 2016 - Wiley Online Library
Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKI s) are
remarkably effective for treating EGFR‐mutant non‐small cell lung cancer (NSCLC) …
remarkably effective for treating EGFR‐mutant non‐small cell lung cancer (NSCLC) …
Treatment outcomes of EGFR-TKI with or without locoregional brain therapy in advanced EGFR-mutant non-small cell lung cancer patients with brain metastases
TH Thinh, NV Hieu, NM Duc - Contemporary Oncology/Współczesna …, 2023 - termedia.pl
Results: Epidermal growth factor receptor tyrosine kinase inhibitor monotherapy patients
had better performance status (PS), fewer CNS symptoms, and significantly fewer brain …
had better performance status (PS), fewer CNS symptoms, and significantly fewer brain …